What If mRNA Vaccines Could Cure Cancer?

Asia's Tech News Daily

Two years ago, approximately nobody on Earth had ever heard of mRNA vaccines. This was for the very good reason that no country had every authorized one. As a scientific experiment, synthetic mRNA was more than 40 years old. As a product, it had yet to be born.

© The Atlantic

Last year, mRNA technology powered the two fastest vaccine developments in history. Moderna famously prepared its COVID-vaccine recipe in about 48 hours. And then there’s BioNTech, a German biotech firm that originally partnered with Pfizer to develop flu therapies but moved quickly to produce its own shot for the new disease. Within 24 hours of the genetic sequencing of the coronavirus, BioNTech had built eight potential vaccine candidates. The company eventually tested more than 20. One of them has now been administered more than 1 billion times around the world—including more than 200 million doses in the United States alone.

[Derek Thompson: How mRNA technology could change the world ]

Messenger ribonucleic acid—or mRNA—is a tiny molecule that instructs our cells to make proteins that keep us alive. Synthetic-mRNA technology, which powers the COVID-19 vaccines from Moderna and Pfizer-BioNTech, sends specialized instructions to our cells to manufacture specific proteins: in this case, the spike protein that encircles the coronavirus. Our immune system trains itself against these harmless spike proteins so that later, if we confront the real coronavirus, our bodies are primed to destroy it. BioNTech’s founders, the husband-and-wife team of Uğur Şahin and Özlem Türeci, compare this to displaying a Wanted poster of an outlaw to our immune system, so that he can be swiftly eliminated when he shows his face.

The fact that mRNA technology had never delivered an authorized therapy before the coronavirus pandemic could tell us one of two things. Perhaps synthetic mRNA is like a miraculous key that humankind pulled out of our pockets in this pandemic, but it was so perfectly shaped for the coronavirus that we shouldn’t expect it to unlock other scientific mysteries any time soon.

Or perhaps mRNA is merely in the first chapter of a more extraordinary story. This month, BioNTech announced that it had initiated Phase 2 trials of personalized cancer vaccines for patients with colorectal cancer. It is working on other personalized cancer vaccines and exploring possible therapies for malaria using a version of the mRNA technology that had its breakout moment in 2020.

Last week, I spoke with Şahin and Türeci about the history of their COVID vaccine and the promise of mRNA. Our conversation left me feeling optimistic about the future of biotechnology, humbled by the extraordinary challenge of commandeering novel technology to eliminate complex diseases, and deeply fortunate that mRNA tech emerged at the perfect moment in the pandemic. This conversation has been edited for length and clarity.

Derek Thompson: BioNTech was founded in 2008 to focus on cancer therapies. How did you wind your way to mRNA technology?

Uğur Şahin: In the early 1990s, we were both cancer physicians working in parallel on taking care of cancer patients by day and working in labs in the evening. At the time, we could only offer chemotherapy and radiation, and very often we had to tell our patients there were no more options for further treatment. But in the lab, we were seeing the promise of new immunology treatments. There was a clear gap between what we could offer patients, on the one hand, and the emerging science, on the other hand. We wanted to overcome this gap.

Özlem Türeci: In the late 1990s, we became interested in mRNA and its potential for vaccination. You could essentially present to our immune system the blueprint of a wanted foe, in this case the cancer and its specific molecules. Then you could deliver instructions to act upon that wanted poster and destroy the foe.

We thought mRNA had huge potential but also many flaws. In the late 1990s, its potency was very low. There was very little effect on the immune system. So that was our research focus for 30 years. Today’s COVID-19 vaccine uses just 30 micrograms of mRNA. That is a tiny amount of mRNA to activate the immune system of the whole body. It’s almost magic to generate billions of immune cells from such a small amount of mRNA.

Thompson: What did you learn that was so special about mRNA technology?

Türeci: Through years of research, we learned we can treat infectious diseases with mRNA by showing our immune system a wanted poster of a foe—like the spike protein on the coronavirus—and instructing the immune system to target that outlaw for destruction. We’ve also learned that, in addition to showing the wanted poster, we can also modify the message that we send to the body. It’s possible that we can treat autoimmune diseases with mRNA by sending a message that tells our cells to do nothing when they see a certain protein.

[Read: The mRNA vaccines are looking better and better]

Thompson: Moderna has a very famous origin story for its COVID-19 vaccine, which is that it finalized the vaccine recipe in 48 hours. Did you design your vaccine in 48 hours too?

Şahin: Actually, we did it in less than 48 hours! In 24 hours, we generated the genetic sequence of the first eight vaccine candidates.

Thompson: Why make eight different vaccines?

Şahin: When we started the project, this was a new virus without any proven vaccine. So it was not clear what was the best molecule to target. From the beginning, Moderna bet on the full spike protein. But at that time, it wasn’t obvious to us that targeting the spike protein was the best. So we developed one vaccine to target the spike and other vaccines to target other parts of the virus.

We ultimately tested about 20 vaccine candidates on mice. We injected animals and varied the dose to understand which vaccines provided the strongest antibody response and T-cell response and protein-antigen production in the mice. Then we took the four most successful candidates to Phase 1 trials. Those Phase 1 trials told us the single vaccine that worked the best. That’s the final vaccine that showed more than 90 percent efficacy in Phase 3 trials and was authorized by the FDA.

Thompson: Obviously, mRNA’s success was a wonderful surprise. But I think it’s underrated just how surprising it really was. It’s doubly surprising to me not only that this technology worked but that it crushed all these land-speed records for vaccine development with extraordinary effectiveness. That mRNA technology was so well suited for this pandemic seems quite wonderful to the point of being almost miraculous. How do you explain why this technology worked so well for this foe?

Şahin: Nobody has ever asked us the question like that before. I think it may be the mother of all questions. Before corona, there was Ebola, and a different vaccine technology that was viral-vector-based was sufficient. [Editor’s note: Viral-vector vaccines, such as the Johnson & Johnson shot, use a harmless version of an unrelated virus to deliver information that teaches cells to produce an antigen, such as the spike protein, that the immune system learns to neutralize.] Ebola was low-hanging fruit for viral-vector-vaccine technology.

The coronavirus is a very different virus. It has these spike proteins that bind very strongly to the receptors [of our cells]. It turned out that mRNA vaccines were particularly excellent for boosting the immune system’s response. So maybe the coronavirus was lower-hanging fruit for mRNA technology.

Thompson: This is why it’s so important to fund different kinds of vaccine technology. Different tools work for different problems, and there’s no guarantee that mRNA will be the perfect tool for the next epidemic.

I want to ask about the other mRNA vaccines you’re working on. Let’s start with malaria. This year, Yale researchers patented an RNA-based technology to vaccinate against malaria. Reuters reported that you plan to start clinical trials for a malaria vaccine by the end of next year. Why do you think mRNA is a good candidate for malaria?

Şahin: Malaria is a field where scientists have been working for decades. This is a pathogen with many escape mechanisms that have eluded other vaccine technologies. Our strategy is to identify new molecular targets that other scientists have overlooked. We are now testing more than 40 malaria-vaccine candidates in preclinical settings. We believe that mRNA vaccines could, if developed properly, provide a lot of opportunities to prevent infection and disease.

Thompson: I also read that you recently dosed your first patient in a 200-person trial of a new cancer vaccine. How do your cancer vaccines work?

Türeci: We have two types of mRNA vaccines for cancer. First, we have our off-the-shelf vaccines, where we’ve identified molecular features of tumors that are shared by many patients. These are molecules that are broadly present in cancer cells but not in normal cells. By targeting these molecules, you can fight the cancer without getting collateral damage to healthy cells. Second, we have highly personalized vaccines. We identify cancer mutations that are unique to every patient. Every cancer patient has their own mutations, like a fingerprint. We biopsy the tumor, sequence it, and design a unique, individualized vaccine for each patient.

For both types of therapies, we have shown, in early clinical trials, that they are safe and that the tumors shrink. We have moved our vaccine development into Phase 2 trials for melanoma and head and neck cancers. We have also started our treatment for individualized vaccines for high-risk colorectal cancer.

Thompson: So you’re working on two types of cancer vaccines. Are they meant for different kinds of cancers?

Şahin: For personalized vaccines, we’ve come to think that focusing on the stage after surgery might be best. After surgery to remove a tumor, about 60 percent of patients are cured. But 30 to 40 percent see regrowth of that tumor. Certain cancers, like lung and liver cancer, are particularly likely to relapse post-surgery. mRNA vaccines could be perfectly suited to block this recurrence by specifically targeting the molecules associated with regrowth and metastasis.

Thompson: Given that vaccines historically have taken years to be developed, how fast can you reasonably produce an individualized cancer vaccine?

Türeci: mRNA technology is fast enough that we can really accelerate this turnaround time. From tumor biopsy to delivery, we can do this in four to six weeks. Every production of an individualized vaccine is a race against that patient’s tumor.

Thompson: How promising are the data so far?

Şahin: We have hundreds of patients worldwide, and the data in the early trials are convincing. That’s why we’ve moved to Phase 2 trials. But it’s important to say that the Phase 2 stage is where we have to prove that our therapy beats the standard of care that the patient would otherwise get. It would only be scientifically sound to gauge the vaccines after this head-to-head comparison. We think we can make major advances in the next five years, but it really depends on what these Phase 2 studies show us.

Internet Explorer Channel Network
Asia's Tech News Daily
News Related

OTHER NEWS

Myanmar security forces ram car into protest in Yangon, deaths feared

(Reuters) – Myanmar security forces in a car rammed into an anti-coup protest on Sunday morning in Yangon, with at least half a <a href="/tag/dozen-protesters”>dozen protesters arrested and dozens injured, ... Read more »

Indian villagers protest as army kills 13, fearing rebels

GAUHATI, India (AP) — Angry villagers burned army vehicles in protest after more than a dozen people were killed by soldiers who mistakenly believed some of them were militants in ... Read more »

Opinion: Cincinnati barbarians are at the gate of the College Football Playoff. Let them in

CINCINNATI — The instant the game ended, the fans poured on to the Nippert Stadium turf. From the press box way up high, they resembled ants atop a picnic table, ... Read more »

Dean buzzer-beater carries Hampton past Norfolk St., 58-57

HAMPTON, Va. (AP) — Russell Dean stepped between two defenders and launched a deep three-pointer at the buzzer to give Hampton a 58-57 win over Norfolk State on Saturday night. ... Read more »

Dad of a Parkland victim blasts GOP lawmaker who shared a Christmas photo of his family smiling with guns and asking Santa to 'please bring ammo'

Rep Thomas Massie (R-KY) draws a Ruger LCP handgun from his pocket during a rally in support of the Second Amendment on January 31, 2020 in Frankfort, Kentucky.Bryan Woolston/Getty Images ... Read more »

No. 18 Oregon holds off late Portland rally, 62-59

PORTLAND, Ore. (AP) — Sydney Parrish and Sedona Prince combined to score 48 points as the No. 18 Oregon women held off a late Portland rally to earn a 62-59 ... Read more »

No. 2 Michigan takes Big Ten in rout, makes playoff pitch

INDIANAPOLIS (AP) — Hassan Haskins ran for two second-half touchdowns and broke a school record while running back Donavan Edwards threw a 75-yard TD pass to help No. 2 Michigan ... Read more »

Big Ten championship: Michigan locks up playoff slot with 42-3 win over Iowa

INDIANAPOLIS — For the first time 2004, Michigan football has won the Big Ten. And now, the Wolverines get a chance to play for a national championship. Several big plays ... Read more »

Maddox Jr. lifts CS Fullerton over Pacific 66-57

FULLERTON, Calif. (AP) — Tray Maddox Jr. had 21 points as Cal State Fullerton defeated Pacific 66-57 on Saturday. E.J. Anosike had 14 points and eight rebounds for Cal State ... Read more »

Cone scores 24 to lift N. Arizona over Idaho St. 73-70

POCATELLO, Idaho (AP) — Jalen Cone had 24 points as Northern Arizona narrowly beat Idaho State 73-70 in a Big Sky Conference game on Saturday night. Mason Stark had 17 ... Read more »

Brewer leads East Tennessee State to lopsided victory

JOHNSON CITY, Tenn. (AP) — Ledarrius Brewer registered 19 points and nine rebounds as East Tennessee State rolled past Lenoir-Rhyne 90-66 on Saturday night. Charlie Weber had 17 points for ... Read more »

Lufile carries Oral Roberts past Houston Baptist 85-67

HOUSTON (AP) — Elijah Lufile tallied 13 points and 11 rebounds to lift Oral Roberts to an 85-67 win over Houston Baptist on Saturday night. Max Abmas had 18 points ... Read more »

Teravainen scores twice, Hurricanes sock Sabres 6-2

RALEIGH, N.C. (AP) — Teuvo Teravainen scored two goals and the Carolina Hurricanes rode an early burst of offense to a 6-2 win over the Buffalo Sabres on Saturday night. ... Read more »

Spurs withstand Warriors' rally for 112-107 victory

SAN FRANCISCO (AP) — Derrick White scored 25 points, Dejounte Murray had 22 points and 12 rebounds, and the San Antonio Spurs held off a furious rally to beat the ... Read more »

Kaprizov gets shootout winner; Wild beat Maple Leafs 4-3

ST. PAUL, Minn. (AP) — Kirill Kaprizov scored in the third round of a shootout and the Minnesota Wild beat the Toronto Maple Leafs 4=3 Saturday night for their sixth ... Read more »

No. 16 Alabama takes down No. 3 Gonzaga 91-82

SEATTLE (AP) — When Nate Oats said yes to the idea of Alabama making the trip to the Pacific Northwest and playing a glorified home game against Gonzaga, he knew ... Read more »

Jones lifts Weber St. over Portland St. 80-69

OGDEN, Utah (AP) — Dillon Jones had 12 points and 14 rebounds to lift Weber State to an 80-69 win over Portland State on Saturday night, the Wildcats’ eighth straight ... Read more »

Martin scores 22 to carry Kansas City past Calvary 94-32

KANSAS CITY, Mo. (AP) — Sam Martin had a career-high 22 points as Kansas City rolled past Calvary 94-32 on Saturday night. Martin shot 4 for 6 on 3-pointers. Anderson ... Read more »

Alabama's O-line comes up big in SEC championship vs Georgia

ATLANTA (AP) — Alabama’s blockers went from being bullied to dominant in the span of a week. The fourth-ranked Crimson Tide’s offensive line rose to the occasion against No. 1 ... Read more »

AP source: Napier gets 7-year, $51.8M contract at Florida

GAINEVILLE, Fla. (AP) — Billy Napier more than tripled his salary while moving from the Sun Belt to the Southeastern Conference. A person familiar with negotiations says Florida’s newest football ... Read more »

Red Wings hand Islanders 10th straight loss, 4-3 in OT

DETROIT (AP) — Moritz Seider scored 3:33 into overtime and the Detroit Red Wings beat the Islanders 4-3 Saturday night, handing New York its 10th straight loss. Filip Hronek, Sam ... Read more »

Grizzlies hang on to beat Mavericks 97-90 after 73-point win

DALLAS (AP) — Desmond Bane scored a career-high 29 points, and the Memphis Grizzlies held on to beat the Dallas Mavericks 97-90 on Saturday night in their first game since ... Read more »

Mississippi, coach Lane Kiffin agree to new contract

OXFORD, Miss. (AP) — Mississippi and Lane Kiffin have agreed to a new contract after the program’s first 10-win regular season. Vice Chancellor for Intercollegiate Athletics Keith Carter Saturday announced ... Read more »

NYPD rookie charged with stalking ex-girlfriend

A rookie NYPD cop was arrested for stalking his ex-girlfriend, police and law enforcement sources said Saturday. Officer Jonathan Pierre-Lys, 31, is accused of tracking his ex’s whereabouts in Queens, ... Read more »

Ramaphosa: ‘We shouldn't panic over the Omicron variant'

© Provided by The South African President Cyril Ramaphosa is calling for calm amongst South Africans, particularly those who are concerned about the emergence of the Omicron variant. It’s been ... Read more »

Alex Ovechkin scores 750th career goal as Washington Capitals top Columbus Blue Jackets

WASHINGTON (AP) — Alex Ovechkin found a new goaltender to score on for another milestone goal, though this time the name rang a bell. Ovechkin beat Daniil Tarasov for his ... Read more »

Strome, Panarin lead Rangers to 3-2 win over Blackhawks

NEW YORK (AP) — Artemi Panarin and Ryan Strome each had a goal and two assists, and the New York Rangers beat the Chicago Blackhawks 3-2 on Saturday night for ... Read more »

Bucks rout short-handed Heat 124-102 without Antetokounmpo

MILWAUKEE (AP) — Pat Connaughton made seven 3-pointers and scored 23 points, and the Milwaukee Bucks avenged an embarrassing loss from the second game of the season, beating the Miami ... Read more »

Quintana leads Loyola Marymount over Long Beach State 77-74

LONG BEACH, Calif. (AP) — Joe Quintana had 20 points as Loyola Marymount rallied from a seven-point halftime deficit to beat Long Beach State 77-74 on Saturday. Dameane Douglas had ... Read more »

LaVine, DeRozan lead Bulls to 111-107 win over Nets

NEW YORK (AP) — Zach LaVine scored 31 points, DeMar DeRozan had 29 and the Chicago Bulls beat the Brooklyn Nets 111-107 on Saturday night. Nikola Vucevic and Ayo Dosunmu ... Read more »

Help fight Covid, recover from it and check if you have antibodies with these products

EVERYONE’S talking about Covid again – so today we look at ways to help you fight it, recover from it and check to see if you have antibodies to it ... Read more »

Attorneys open nonprofit: 'There shouldn't be a price tag on stopping childhood trauma'

Attorney Theresa Jenkins talks on Thursday, Dec. 2, 2021, outside the historic Brighton building she has acquired to serve as offices for the Justice Lawyer League. Theresa Jenkins grew up ... Read more »

Robinson carries Fresno St. past CS Northridge 61-43

FRESNO, Calif. (AP) — Orlando Robinson had 22 points as Fresno State got past Cal State Northridge 61-43 on Saturday. Deon Stroud had 14 points for Fresno State (7-1), which ... Read more »

Tkachuk scores early in OT, leads Senators past Avalanche

OTTAWA, Ontario (AP) — Brady Tkachuk scored his second goal 51 seconds into overtime, giving the Ottawa Senators a 6-5 win over the Colorado Avalanche on Saturday night. Tkachuk added ... Read more »

No. 5 Baylor holds off Missouri behind Smith's double-double

WACO, Texas (AP) — NaLyssa Smith had her eighth consecutive double-double with 25 points and 17 rebounds, and fifth-ranked Baylor handed Missouri its first loss of the season with a ... Read more »

Samuel carries Florida Gulf Coast past Dartmouth 78-68 in OT

FORT MYERS, Fla. (AP) — Kevin Samuel recorded 19 points and 12 rebounds to lift Florida Gulf Coast to a 78-68 overtime win over Dartmouth on Saturday night. Cyrus Largie ... Read more »

Hannibal leads Murray St. past Middle Tennessee 93-87

MURRAY, Ky. (AP) — Trae Hannibal scored 19 points as Murray State defeated Middle Tennessee 93-87 on Saturday night. KJ Williams and Justice Hill added 18 points apiece for the ... Read more »

No. 5 Baylor women hand Missouri first loss, 70-68

WACO, Texas (AP) — NaLyssa Smith had her eighth consecutive double-double with 25 points and 17 rebounds, and fifth-ranked Baylor handed Missouri its first loss of the season, 70-68 in ... Read more »

Ovechkin nets 750th career goal, Caps beat Blue Jackets 3-1

WASHINGTON (AP) — Alex Ovechkin scored his 20th goal of the season and the 750th of his NHL career to help the Washington Capitals beat the Columbus Blue Jackets 3-1 ... Read more »

Gun used in Michigan school shooting was an apparent Christmas present: prosecutors

A memorial outside of Oxford High School continues to grow on December 03 2021 in Oxford, Michigan.Scott Olson/Getty Images Oakland County's prosecutor said the gun used in the Oxford High ... Read more »
On free-english-test.com you will find lots of free English exam practice materials to help you improve your English skills: grammar, listening, reading, writing, ielts, toeic